Search
Betta Pharmaceuticals Announces Marketing Approval for Ensartinib Hydrochloride Capsules in Macau
5 day ago /
Read about 0 minute
Author：小编
Betta Pharmaceuticals is pleased to announce that Ensartinib Hydrochloride Capsules (trade name: Beimeina®) have recently received marketing approval from the Macao Drug Regulatory Authority. This groundbreaking medication is indicated for the treatment of patients diagnosed with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. Ensartinib Hydrochloride Capsules represent a collaborative effort between Betta Pharmaceuticals and its holding subsidiary, Xcovery, and boast fully independent intellectual property rights.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
